In vitro activities of novel des-fluoro(6) quinolone BMS-284756 against mutants of Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus selected with different quinolones.

نویسندگان

  • Franz-Josef Schmitz
  • Mechthild Boos
  • Susanne Mayer
  • Karl Köhrer
  • Sibylle Scheuring
  • Ad C Fluit
چکیده

BMS-284756 (T-3811) is a novel quinolone that lacks a fluorine at the C-6 position. BMS-284756 has a broad spectrum of antibacterial activity (3, 7). The purpose of the present study was (i) to analyze the in vitro activity of the novel quinolone against mutants of Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus selected with marketed quinolones and (ii) to investigate whether this compound is a substrate for efflux pumps. In order to analyze these therapeutically important aspects, we repeatedly exposed six clinical strains of each species to ciprofloxacin, gatifloxacin, moxifloxacin, and BMS-284756, as described previously for several other quinolones (1). MICs were determined using microdilution methodology according to NCCLS guidelines (5). MIC determinations for BMS-284756 were conducted in the presence and absence of reserpine (20 g/ml; tests were repeated three times) for all of the original isolates (n 18) as well as for all of the selected mutants (n 72) (1, 2). In addition, isolates were analyzed before and after transfers for mutations in the quinolone-resistance determining regions of parC or grlA and gyrA (4, 6, 8). The MIC results from subculturing as well as the alterations in the quinolone resistance-determining regions are listed in Table 1, which presents a summary of results for each species tested, highlighting the range of events seen. BMS-284756 (range, 0.004 to 0.06 g/ml) exhibited the best in vitro activities against all 18 original isolates, followed by moxifloxacin (range, 0.03 to 0.25 g/ml) and gatifloxacin (range, 0.06 to 0.5 g/ml). Ciprofloxacin (range, 0.125 to 2 g/ml) showed the lowest in vitro activities. Furthermore, BMS-284756 (range, 0.015 to 8 g/ml) exhibited the best in vitro activities against all 72 selected mutants, followed by moxifloxacin (range, 0.06 to 64 g/ml), gatifloxacin (range, 0.06 to 128 g/ml), and ciprofloxacin (range, 0.25 to 256 g/ml) (Table 1). None of the original 18 strains and none of the 72 selected mutants displayed lower MICs for BMS-284756 in the presence of reserpine. These results illustrate that the novel quinolone is not a good substrate for efflux pumps. Based on the results presented, i.e., twoto ninefold increases in MICs after passages in BMS-284756-containing medium, the new quinolone seems to have the same potential for resistance development as that of the C-8 methoxy quinolones gatifloxacin and moxifloxacin. Alterations in ParC (S79Y or S79F) and GyrA (S81F) contributed to the resistance seen in S. pneumoniae mutants selected by BMS-284756. In Streptococcus pyogenes mutants, alterations in ParC (S79A and S79F) and GyrA (S81Y or E85G) were found. In addition, classical alterations in GrlA (S80Y, S80F, or E84K) and GyrA (S84L) contributed to the resistance in S. aureus mutants selected by BMS-284756. These classical alterations are identical to those observed in isolates selected by other quinolones (4, 6, 8). In summary, the new quinolone BMS-84756 has good in vitro activity against wild-type isolates and selected mutants of Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus. The novel quinolone is not a good substrate for efflux. BMS-84756 seems to have the same potential for resistance development as that of the C-8 methoxy quinolones gatifloxacin and moxifloxacin.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Staphylococcus aureus mutants selected by BMS-284756.

BMS-284756, a novel des-fluoro(6)-quinolone, was used to select for in vitro mutants of Staphylococcus aureus ISP794. Step mutants were obtained, and the quinolone resistance-determining regions of four target genes, gyrA, gyrB, grlA, and grlB, were sequenced. The data suggest that DNA gyrase is the primary target for BMS-284756 in S. aureus.

متن کامل

BMS284756 (formerly T-3811, a des-fluoroquinolone) potency and spectrum tested against over 10,000 bacterial bloodstream infection isolates from the SENTRY antimicrobial surveillance programme (2000).

BMS284756 is a novel des-F (6)-quinolone, which has a wide range of activity against many species of Gram-positive and -negative organisms. The potency of BMS284756 was compared with that of other quinolones, including ciprofloxacin, gatifloxacin and levofloxacin, and was tested against >10,000 bloodstream isolates from the year 2000 SENTRY antimicrobial surveillance programme. Twelve pathogens...

متن کامل

The inhibition and selectivity of bacterial topoisomerases by BMS-284756 and its analogues.

Analogues of BMS-284756, a novel des-F(6)-quinolone, were synthesized and evaluated in order to determine the effects of modification of substituents on in vitro target inhibition. BMS-340281 (stereoisomer of BMS-284756), BMS-340280 (C-6 fluorinated analogue of BMS-284756), BMS-340278 (C-8-H derivative), BMS-433366 (C-8 methoxy analogue) and fluoroquinolone comparators were evaluated for antiba...

متن کامل

Induction of in vitro resistance to BMS-284756 by Streptococcus pneumoniae.

Sir, BMS-284756 (T-3811) is a novel quinolone that lacks a fluorine at the C-6 position, and is active in vitro against Streptococcus pneumoniae, including strains with elevated ciprofloxacin MICs. Because the various quinolones differ in both target affinity and their activation of efflux pumps, one can speculate that the phenotypic expression of quinolone resistance will also differ. Studies ...

متن کامل

In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone.

The in vitro antibacterial activity of AM-1155 against a wide variety of clinical isolates was compared with those of other fluoroquinolones. The MICs of AM-1155 for 90% of Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecalis isolates tested were 0.10, 0.39, and 0.78 microgram/ml, respectively. The antibacterial activity of AM-1155 against gram-positive bacteria and anaero...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Antimicrobial agents and chemotherapy

دوره 46 3  شماره 

صفحات  -

تاریخ انتشار 2002